Press Release

View printer-friendly version

<<  Back

Geron Corporation to Present at BIO CEO & Investor Conference

MENLO PARK, Calif., Feb. 9, 2007 – Geron Corporation (Nasdaq: GERN) will present an update of the company’s product development programs at 1:15 p.m. ET on Monday, Feb. 12, 2007, at the BIO CEO & Investor Conference in New York City.

The update of Geron’s portfolio of telomerase–based anti–cancer therapies will include the inhibitor drug, GRN163L, and the therapeutic vaccine, GRNVAC1. The presentation will also include reviews of the company’s human embryonic stem cell (hESC) development programs for spinal cord injury (GRNOPC1), heart disease (GRNCM1) and diabetes (GRNIC1). Thomas B. Okarma, Ph.D., M.D., Geron’s president and chief executive officer, will be giving the presentation.

An audio webcast of the presentation will be available at the following website address: http://www.corporate–ir.net/ireye/conflobby.zhtml?ticker=GERN&item_id=1466840. A replay will be available at this address within 24 hours of the presentation and for a period of 30 days.

Geron is developing first–in–class biopharmaceuticals for the treatment of cancer and degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS. The company is advancing an anticancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. Geron is also the world leader in the development of human embryonic stem cell–based therapeutics, with its spinal cord injury treatment poised to be the first product to enter clinical development. For more information, visit www.geron.com.

CONTACTS:

Media: David Schull, Noonan Russo, 858–717–2310, david.schull@eurorscg.com

Investors: Matthew Haines, Noonan Russo, 212–845–4235, matthew.haines@eurorscg.com

At Geron: David L. Greenwood, Chief Financial Officer, 650–473–7765, info@geron.com

# # #